| ¿µ¹® | drug resistance | ÇÑ±Û | ¾à¹°³»¼º |
|---|---|---|---|
| ¼³¸í | 1. ÈÇпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ ÈÇпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈµÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ ÀÖ´Â ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ ÀÖ´Â ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇÏ¸é ³»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇÏ´Â °Í µîÀÌ ±× ¿¹ÀÌ´Ù. |
||
| ¿µ¹® | drug dependence | ÇÑ±Û | ¾à¹°ÀÇÁ¸(¼º) |
|---|---|---|---|
| ¼³¸í | ¾î¶² Á¾·ùÀÇ ¾à¹°À» ¹Ýº¹Çؼ »ç¿ëÇÏ´Â µ¿¾È ±× ¾àÀÇ »ç¿ëÀ» ÁßÁöÇÒ ¼ö ¾ø°Ô µÇ´Â »óÅÂ. ÀÇÁ¸ÀÇ Á¤µµ°¡ ½ÉÇØÁö¸é ¾à ¾øÀÌ´Â »ýȰÇÒ ¼ö ¾ø´Â »óÅ¿¡ ºüÁö°í, ±× °á°ú ¹ýÀ» ¾î±â¸é¼±îÁö ¾àÀ» ±¸ÀÔÇÏ°Ô µÈ´Ù. ÀÌÀü¿¡´Â ¾à¹°¸¸¼ºÁßµ¶, ¾à¹°³²¿ë, ¾à¹°½À°ü¼ºÀ̶ó´Â °³³äÀ¸·Î ³ª´©¾îÁ® ÀÖ¾úÁö¸¸, WHO¿¡¼´Â À̰͵éÀ» ¸ðµÎ Æ÷ÇÔ½ÃÄѼ ¾à¹°ÀÇÁ¸À̶ó ÇÏ¿´´Ù. »óÅ¿¡ ÀÇÇÑ ºÐ·ù¶ó ¾à¹°ÀÛ¿ë¿¡ ÀÇÇÑ ºÐ·ù°¡ ÀÖ´Ù. »óÅ¿¡ ÀÇÇÑ °ÍÀº 1.Á¤½ÅÀû ÀÇÁ¸: ¾à¹°ÀÇ »ç¿ëÀ» ÁßÁöÇÏ¸é ºÒ¾È°¨-¿ì¿ï°¨-ÃÊÁ¶°¨ µîÀÇ ½É¸®ÀûÀÎ Áõ»óÀÌ ³ªÅ¸³ª ´Ù½Ã ¾à¹°À» ã°Ô µÇ´Â °æ¿ì. ¾àÀ» ²÷¾úÀ» °æ¿ì¿¡ ³ªÅ¸³ª´Â ½ÅüÁõ»óÀÎ ±Ý´ÜÁõ»óÀº ³ªÅ¸³ªÁö ¾ÊÀ¸¸ç, ¾à¹°ÀÇ Áö¼ÓÀû º¹¿ë¿¡ ÀÇÇØ¼ Á¡Â÷ ¾à¹°¿¡ ´ëÇÑ ½ÅüÀÇ ¹ÝÀÀÀÌ ÁÙ¾îµå´Â Çö»óÀÎ ¾à¹°ÀÇ ³»¼ºµµ ³ªÅ¸³ªÁö ¾Ê´Â´Ù. 2.½ÅüÀû ÀÇÁ¸: ¾à¹° »ç¿ëÀ» ÁßÁöÇÏ¸é ½ÅüÀûÀÎ Àå¾Ö, Áï ±Ý´ÜÁõ»óÀ» ÀÏÀ¸Å°°í ±× °íÅëÀ» ´Þ·¡±â À§ÇØ ¾à¹°À» ã°Ô µÇ´Â °æ¿ìÀÌ´Ù. ´ëºÎºÐ ³»¼ºÀÌ ³ªÅ¸³ª´Âµ¥ °³º°ÀûÀ¸·Î ³ªÅ¸³ª´Â °æ¿ìµµ ÀÖÁö¸¸ ÁÖ·Î º´ÇàÇØ¼ ³ªÅ¸³´Ù. |
||
| ¿µ¹® | antianginal drug | ÇÑ±Û | Ç×Çù½ÉÁõÁ¦ |
|---|---|---|---|
| ¼³¸í | Çù½ÉÁõÀº ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°ÔÇϰųª ½ÉÀåÀÌ Ç÷·ù¿¡ ºñÇØ¼ ¸¹Àº ÀÏÀ» ÇÏ´Â °ÍÀ» ¾ïÁ¦ÇÔÀ¸·Î½á Ä¡·áµÉ ¼ö ÀÖ´Ù. ¨ç nitrate°èÅëÀÇ ¾à¹°: Ç÷°üÀ» À̿ϽÃŰ´Â ÀÛ¿ëÀ» ÇÔÀ¸·Î½á ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù. ¨è Ä®½·Åë·ÎÂ÷´ÜÁ¦(verapamil, nifedipine): ¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â CaÀÌ °ü¿©ÇÑ´Ù. Áï CaÀÌ ÀÖ¾î¾ß¸¸ ±ÙÀ°ÀÇ ¼öÃàÀÌ °¡´ÉÇØÁø´Ù. ±×·¯¹Ç·Î CaÀÌ ¼¼Æ÷¼ÓÀ¸·Î µé¾î°¡´Â °ÍÀ» ¾ïÁ¦ÇÏ´Â ¾àÁ¦´Â ±ÙÀ°ÀÇ ¼öÃàÀ» ¸·´Â´Ù. ÀÌ ¾àÀº ½ÉÀåÀÇ ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ½ÉÀå ±ÙÀ°ÀÇ ¼öÃàÀ» ¾ïÁ¦ÇÏ¸ç ½ÉÀåÀÌ °úµµÇÏ°Ô ÀÏÇÏ´Â °ÍÀ» ¸·°í, ¶Ç ½ÉÀ嵿¸ÆÀÇ ¼öÃà¿¡ °ü¿©ÇÏ´Â ±ÙÀ°¿¡ ÀÛ¿ëÀ» ÇÏ¿© ½ÉÀ嵿¸ÆÀ» À̿ϽÃÄѼ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù. ¨é º£Å¸Â÷´ÜÁ¦(beta-blocker): ½ÅüÀÇ ¿îµ¿·®À̳ª ±âŸÀÇ ¿ä±¸¿¡ ÀÇÇØ¼ ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇÏ´Â ½Å°æÀº ¹Ù·Î º£Å¸-±³°¨½Å°æÀÌ´Ù. ±³°¨½Å°æ°è¶õ »ç¶÷ÀÌ À§±ÞÇÑ »óȲ¿¡¼ ÀÛ¿ëÇÏ´Â ÀÚÀ²½Å°æ°èÀÌ´Ù. Áï »ç¶÷ÀÌ ±äÀåÇϰųª ½Î¿ï °æ¿ì¿¡ ÀüÇüÀûÀ¸·Î ±³°¨½Å°æ°è°¡ ÀÛ¿ëÇÑ´Ù. Áï ½ÉÀåÀÌ ¶Ù°Å³ª ¼ÒȰ¡ ¾ÊµÇ°Å³ª µ¿°øÀÌ Ä¿Áö´Â °Í µûÀ§°¡ ¹Ù·Î ±³°¨½Å°æ°èÀÇ ¿ªÇÒÀ̶ó°í ÇÒ ¼ö ÀÖ´Ù. ÀÌ ±³°¨½Å°æ°è¿¡¼ ¸»ÃÊÀå±â¿¡ º¸³»´Â ½Å°æÀÌ ±³°¨½Å°æÀÌ´Ù. ±×·¯¹Ç·Î ½ÉÀå¿¡¼ ½ÉÀåÀ» ½Åü¿¡ Çʿ信 µû¶ó¼ ¸¹Àº ÀÏÀ» ÇϰÔÇÏ´Â ½Å°æÀ» Â÷´ÜÇÒ °æ¿ì¿¡´Â Çù½ÉÁõÀ» Ä¡·áÇÒ ¼ö ÀÖ°Ô µÈ´Ù(½ÉÀåÀÇ »ê¼Ò³ª ±âŸ ¿µ¾çºÐÀÇ ¼ö¿ä¸¦ ÁÙÀδÙ). |
||
| ¿µ¹® | test | ÇÑ±Û | °Ë»ç |
|---|---|---|---|
| ¼³¸í | ¾î¶² ´Ù¸¥ ¹°ÁúÀ» °ËÃâ, ÃøÁ¤, »ý¼ºÇϱâ À§ÇÑ Æ¯Á¤ÇÑ ÈÇйÝÀÀÀ» ÀÏÀ¸Å°´Âµ¥ »ç¿ëµÇ´Â ¹æ¹ý. |
||
| ¿µ¹® | scratch test | ÇÑ±Û | ³Àý¹ý |
|---|---|---|---|
| ¼³¸í | ÇǺθ¦ ³¯Ä«·Î¿î ¹Ù´Ã·Î ±Ü¾î ÇǺÎÀÇ ¹ÝÀÀÀ» º¸´Â °Ë»ç·Î ÇǺΠ°ú¹Î¹ÝÀÀÀ̳ª ¾Ë·¹¸£±â¸¦ ¾Ë¾Æº¸±â À§ÇÑ °Ë»çÀÌ´Ù. ¹Ù´Ã³¡¿¡ Ç׿øÀ» ¹¯Èù µÚ, ÇǺιØÀ» ±Ü¾î ¹ÝÀÀÀ» ¾Ë¾Æº»´Ù. À̶§ Ç׿øÀÌ ¾Æ´Ñ ´ëÁ¶¹°Áú(¿¹¸¦ µé¾î º¸ÅëÀÇ ¹°)À» ¹¯Èù ¹Ù´ÃÀ» °°ÀÌ ¹ÝÀÀÇÏ¿© ÇǺ馱âÁõ(dermographism) ´ÜÁö ¹Ù´ÃÀÇ ±ÜÈû¸¸À¸·Î ¾Ë·¹¸£±â °°Àº ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Çö»ó°ú °¨º°ÇØ¾ß ÇÑ´Ù. ³Ã», û·Â¼Ò½Ç(hearing loss) û°¢ÀÌ ÀúÇÏ ¶Ç´Â »ó½ÇµÈ »óÅÂ. ¿øÀΰú Á¤µµ´Â ¿©·¯ °¡ÁöÀε¥, ³Ã»Àº ±× Á¤µµ°¡ °¡Àå ½ÉÇÑ »óÅÂÀÌ´Ù. û°¢ÀÇ Àüµµ°æ·Î¿¡ Àå¾Ö°¡ ÀÖÀ» ¶§ ³Ã»ÀÌ ÀϾ°í, ±× º´ÅͰ¡ ¿ÜÀ̵µ³ª ÁßÀÌ¿¡ ÀÖ´Â °ÍÀ» ÀüÀ½³Ã», ³»ÀÌ¿¡ ÀÖ´Â °ÍÀ» °¨À½ ³Ã»À̶ó ÇÏ¿© ±¸ºÐÇÑ´Ù. ¶Ç º´ÅÍÀÇ ÀÚ¸®¸¦ ¸í½ÃÇÏ¿© ÁßÀ̼º ³Ã»À̳ª ¹Ì·Î¼º ³Ã» µîÀ¸·Î ¼¼ºÐÇϱ⵵ ÇÑ´Ù. |
||
| ISI | infarct size index; initial slope index; injury severity index; Institute for Scientific Information... |
|---|---|
| MCS | malignant carcinoid syndrome; managed care system; massage of the carotid sinus; mesocaval shunt; me... |
| DAST | drug abuse screening test; drug and alcohol screening test |
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
| CMT | California mastitis test; cancer multistep therapy; catechol methyltransferase; certified medical tr... |
| intrathecal chemotherapy | Treatment with drugs that are injected into the fluid surrounding the brain and spinal cort (cerebrospinal fluid). (12 Dec 1998) |
|---|---|
| topical chemotherapy | Treatment with anticancer drugs in a lotion or cream. (12 Dec 1998) |
| acquired sensitivity | 1. <immunology> A state of hypersensitivity induced by exposure to a particular antigen (allergen) resulting in harmful immunologic reactions on subsequent exposures, the term is usually used to refer to hypersensitivity to an environmental antigen (atopic allergy or contact dermatitis) or to drug allergy. The original meaning, now obsolete, included all states of altered immunologic reactivity, immunity as well as hypersensitivity. Gell and Coombs used the term allergic reaction to mean any harmful immunologic reaction causing tissue injury. 2. <study> The medical specialty dealing with diagnosis and treatment of allergic disorders. (18 Nov 1997) |
| analytical sensitivity | The degree of response to a change in concentration of analyte being measured in an assay; synonymous with the detection limit. (05 Mar 2000) |
| antibiotic sensitivity | Microbial susceptibility to antibiotics. See: antibiotic sensitivity test, minimal inhibitory concentration. (05 Mar 2000) |
| pacemaker sensitivity | The minimum cardiac activity required to consistently trigger a pulse generator. (05 Mar 2000) |
| relative sensitivity | The sensitivity of a medical screening test as determined by comparison with the same type of test; e.g., sensitivity of a new serological test relative to sensitivity of an established serological test. (05 Mar 2000) |
| microbial sensitivity tests | Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). (12 Dec 1998) |
| photoallergic sensitivity | See: photosensitization. (05 Mar 2000) |
| phototoxic sensitivity | See: photosensitization. (05 Mar 2000) |
| clinical sensitivity | Test positivity in disease; ability of a test to correctly identify disease. See: diagnostic sensitivity. (05 Mar 2000) |
| multiple chemical sensitivity | An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61) (12 Dec 1998) |
| contact sensitivity | Allergic response to contact with irritant, usually a hypersensitivity. (18 Nov 1997) |
| contrast sensitivity | The ability to detect sharp boundaries (stimuli) and to detect slight changes in luminance at regions without distinct contours. Psychophysical measurements of this visual function are used to evaluate visual acuity and to detect eye disease. (12 Dec 1998) |
| primaquine sensitivity | Nonimmunological inborn sensitivity to primaquine, causing haemolysis on exposure to the drug, due to deficiency of glucose-6-phosphate dehydrogenase in red cells. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|